Amikacin treatment in patients with Enterobacterales bacteraemia: impact of MIC on mortality
We demonstrated a relation between higher amikacin MIC levels (8 and 16 mg/L) and increased 30-day mortality in patients treated with amikacin for bacteraemia secondary to a urinary source. These findings support the new CLSI breakpoint change of Enterobacterales to amikacin.
Authors
- Debby Ben David
- Yasmin Maor (ORCID: https://orcid.org/0000-0001-7258-3434)
- Orna Schwartz
- Iris Zohar (ORCID: https://orcid.org/0009-0004-5470-2208)
- Adam Pomerantz
- Elinoar Hoffman
- G Caliari
Institutions
- Tel Aviv University (IL)
- Wolfson Medical Center (IL)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2024-09-27
- DOI
- https://doi.org/10.1093/jac/dkae343
- Citations
- 3
- Primary Topic
- Antibiotics Pharmacokinetics and Efficacy
- Type
- article
- Field-Weighted Citation Impact
- 1.34